Chen, J., Zhou, Y., Pang, Y., Fu, K., Luo, Q., Sun, L., Wu, H., Lin, Q., Su, G., Chen, X., Zhao, L., Chen, H.

FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy

12 de January de 2025 by Chen, J., Zhou, Y., Pang, Y., Fu, K., Luo, Q., Sun, L., Wu, H., Lin, Q., Su, G., Chen, X., Zhao, L., Chen, H.

Background
Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, 68Ga/17…